Safety and efficacy of multiuse botulinum toxin vials for intralaryngeal injection
- 4 December 2014
- journal article
- research article
- Published by Wiley in The Laryngoscope
- Vol. 125 (5) , 1149-1154
Abstract
Objectives/Hypothesis: Centers for Disease Control and Prevention guidelines maintain that single‐use vials cannot be used for multiple patients. Botox product labeling states that the reconstituted toxin should be used within 4 hours on a single patient based on concerns of reduced potency, contamination, and consequent infections. The purpose of this study was to determine the safety and efficacy of using single‐use vials in a multidose fashion.Study Design: Prospective study and cohort chart review.Methods: A multi‐institutional three‐part study was performed between May 2013 and October 2013: 1) a summation of subjects' recall of their past experiences (symptoms/response) with previous multidose Botox injections, 2) a prospective study of intralaryngeal injections, and 3) a chart review of injection responses in a subset of the cohort.Results: Seven hundred forty‐three subjects receiving 6,216 injections demonstrated zero infection‐related complications on retrospective chart review. One hundred seventy‐nine subjects recalled 24.0% overall adverse events, 10.6% redness, 7.3% pain and swelling at the injection site, and 0% fever. One hundred seventy‐four subjects prospectively reported 12.6% overall adverse events. The self‐reported efficacy rate of Botox injection was 96.6%.Conclusions: The low rates of adverse events following the use of Botox in a multipatient fashion are consistent with other percutaneous injections. No evidence of infection was found with multidose Botox use. Given the low incidence of side effects and high success rate, Botox can be used both safely and effectively in a multipatient fashion.Level of Evidence: 4 Laryngoscope, 125:1149–1154, 2015Keywords
This publication has 22 references indexed in Scilit:
- An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditionsJRSM Short Reports, 2013
- Injection practices among clinicians in United States health care settingsAmerican Journal of Infection Control, 2010
- Blind Multicenter Study of the Efficacy and Safety of Injections of a Commercial Preparation of Botulinum Toxin Type A Reconstituted up to 15 Days Before InjectionDermatologic Surgery, 2009
- Clinical Efficacy of Botulinum Toxin Type A Reconstituted and Refrigerated 1 Week before Its Application in External Canthus Dynamic LinesDermatologic Surgery, 2007
- Sterility assessment of multiple use botulinum A exotoxin vials: A prospective simulationJournal of the American Academy of Dermatology, 2006
- Microbial growth in vials of Botulinum toxin following use in clinicEye, 2006
- Botulinum toxin type A injections: Adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic casesJournal of the American Academy of Dermatology, 2005
- The story of Clostridium botulinum: from food poisoning to BotoxClinical Medicine, 2004
- Contraindications and complications with the use of botulinum toxinClinics in Dermatology, 2004
- Multicenter, Double-Blind Study of the Efficacy of Injections With Botulinum Toxin Type A Reconstituted Up to Six Consecutive Weeks Before ApplicationDermatologic Surgery, 2003